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Pseudomonas aeruginosa lectin PA-II agglutinates human peripheral ymphocytes and stimulates mitogene- 
sis (predominantly in T cells), like the plant lectins PHA and Con A. Murine splenocytes are also agglutinat- 
ed and stimulated by PA-II as by Con A. Sialidase treatment of the human and murine cells enhances their 
agglutination and augments the stimulation of human lymphocytes at low PA-II concentrations. The PA-II 
agglutinating and mitogenic effects are specifically inhibited by L-fucose. The bacterial source and the speci- 
ficity of PA-II for L-fucose are both rare features among the hitherto described mitogenic lectins. However, 
since this lectin also binds mannose, a mannose-bearing receptor might be involved in its mitogenicity. 
Mitogenic lectin; PA-II lectin; Lymphocyte; (Murine splenocyte, Pseudomonas aeruginosa) 
1. INTRODUCTION 
Mitogenic stimulation in peripheral and splenic 
lymphocytes is one of the most remarkable effects 
possessed by certain lectins. Some of them are 
mitogenic for both T and B lymphocytes while 
others are mitogenic predominantly for T lym- 
phocytes [l] . The mitogenic property is of interest 
both as a biological phenomenon and as a 
diagnostic tool for cytogenetic studies of 
chromosome abnormalities [2] and human diseases 
associated with immunodeficiency [3] or other 
special physiological conditions [4,5,6]. 
We have isolated two lectins, PA-I and PA-II 
from extracts of the bacterium Pseudomonas 
aeruginosa. PA-I is specific for D-galactose and its 
derivatives and PA-II exhibits a higher affinity for 
L-fucose and L-galactose followed by D-mannose. 
Both lectins were shown to resemble plant lectins 
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in their physico-chemical properties and in their ef- 
fects on various types of cells [7]. 
In 1977 we reported that PA-I is mitogenic for 
human peripheral lymphocytes, predominantly T 
cells, pretreated with sialidase [8]. The mitogenic 
effect of PA-I on human lymphocytes was shown 
to be as useful as that of PHA in the diagnosis of 
low responding lymphocytes from cancer patients 
191. 
The present communication demonstrates that 
PA-II is also endowed with mitogenic activity for 
both human peripheral lymphocytes and murine 
splenocytes. This mitogenic stimulation, which is 
comparable to that of the well-known plant lectins 
PHA and Con A, is specifically inhibited by L- 
fucose. 
2. MATERIALS AND METHODS 
The lectins of Pseudomonas aeruginosa were 
purified in our laboratory as described [lo]: 
heating at 7O”C, fractionation by ammonium 
sulfate and affinity chromatography on D- 
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mannose-bearing Sepharose 4B. PHA-M was pur- 
chased from Difco and Con A from Sigma. 
Human peripheral blood lymphocytes were ob- 
tained from heparinized (0.3 mg-ml-‘) blood 
samples of healthy volunteers. They were isolated 
according to Boyum [l l] with lymphoprep 
(Nyegaard, Oslo). Fractionation of the lym- 
phocytes (to T and B) was performed by overnight 
rosette formation using sialidase-treated sheep red 
blood cells [12,13]. The rosette-forming lym- 
phocytes (T-enriched fraction) were separated 
from the B lymphocytes by another centrifugation 
on lymphoprep. The latter were recovered in the 
upper phase while the former were recovered from 
the bottom; both cell fractions were washed twice 
with the culture medium. Red cell lysis in the T 
cell-enriched fraction was obtained by 0.87% 
NH&l at room temperature for 10 min. 
Sialidase-treated lymphocytes were obtained by 
incubating the cells (2 x 107/ml) in saline with 
sialidase (purchased from Behringwerke, Marburg 
Lahn, FRG) at 37°C for 30 min with shaking (50 
units sialidaselml in a solution containing 0.154 M 
NaCl and 9 mM calcium chloride in 0.05 M 
acetate buffer at pH 5.5. The sialidase-treated cells 
were washed twice with PBS and resuspended in 
the RPM1 culture medium containing 10% FCS. 
Murine splenocyte suspensions were obtained by 
pressing whole spleens aseptically removed from 
C57 B1/6J mice (6-10 weeks old), through a sterile 
mesh stainless steel screen (with the use of a 
plunger from a 1 ml syringe) into 5 ml of RPM1 
1640 medium. Cell clumps were removed by 
sedimentation and the cell suspension was washed 
twice with PBS and resuspended in the culture 
medium containing 5% FCS supplemented with 
2-mercaptoethanol (5 x 10e5 M) and L-glutamine 
(2 mM). Viability of the cells determined by the 
trypan blue exclusion test, was usually more than 
90%. 
Agglutination of the cells by the lectins was ex- 
amined using human lymphocytes or murine 
splenocyte suspensions containing 2 x lo6 
cells/ml. An aliquot (0.1 ml) of the cell suspension 
was mixed with an equal volume of either PBS or 
PA-II (100 pg/ml) and incubated at 37°C in a 5% 
CO2 atmosphere for 2 h. The specificity of the lec- 
tin effect was always checked by addition of 
0.05 M L-fucose to the incubation medium. The 
agglutination was examined by phase-contrast 
microscopy. 
The mitogenic assay was performed by suspen- 
ding 1 x lo6 human lymphocytes or 2 x lo6 murine 
splenocytes in 1 ml of the appropriate culture 
medium with or without lectins at final concentra- 
tions as indicated in the text. Samples (0.2 ml) of 
the cells were grown in quadruplicate in a 
microtiter plate (NUNC) at 37°C in a 5% CO2 at- 
mosphere for 72 h. 24 h before harvesting, 1 &i 
[3H]thymidine was added to each culture. The cells 
were harvested onto glass fiber filters with the aid 
of an automatic cell harvester (Linca, Calinca, Tel- 
Aviv) and the [3H]thymidine incorporation was 
determined by liquid scintillation counting. The 
results are expressed as a stimulation index SI, 
which is the ratio of counts in the presence and in 
the absence of the lectin. 
3. RESULTS 
Both human peripheral ymphocytes and murine 
splenocytes were readily agglutinated by PA-II at 
a final lectin concentration of 50pg/ml. The ag- 
glutination of the human cells was somewhat 
stronger than that of the murine cells; sialidase 
treatment of the cells considerably enhanced their 
agglutination and the addition of 0.05 M L-fucose 
to the incubation medium inhibited it. 
PA-II was found to exhibit a remarkable 
mitogenic activity towards human peripheral lym- 
phocytes (tables l-3 and figs 1,2) either treated or 
untreated by sialidase. At low lectin levels (up to 
Table 1 
[3H]Thymidine incorporation into human peripheral 
lymphocytes in the presence of PA-II (compared with 
PHA and Con A) with or without L-fucose 
Mitogen Addition of [3H]Thymidine SIa 
added L-fucose incorporation 
k/ml) (0.05 M) (cpm + SE)a 
- - 1558 f 392 - 
- + 1558 AZ 694 - 
PA-II (60) - 107818 + 8643 69 
+ 2109 + 427 1 
Con A (12.5) - 122783 + 1499 78 
+ 117958 X!Z 7090 76 
PHA (25) - 181883 f 6574 117 
+ 199998 2 2541 128 
a As described in section 2 
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Table 2 
[3H]Thymidine incorporation into human peripheral (untreated and sialidase-treated) 
lymphocytes in the presence of varying concentrations of PA-II 
PA-II 
concentration 
[3H]Thymidine incorporation 
(cpm + SE)a 
SIa 
Cfdml) 
Untreated Sialidase- Untreated Sialidase- 
cells treated cells cells treated cells 
0 1672 + 380 1631 +- 327 
5 2460 +_ 413 19045 + 1271 1 11 
10 8890 f 385 34808 + 4328 5 21 
15 17720 k 1101 72263 + 6445 10 44 
30 74974 k 15028 106493 + 5387 45 65 
60 107818 + 8643 124170 + 3583 64 76 
75 155960 k 25372 145336 + 6103 93 89 
a As described in section 2 
Table 3 
[3H]Thymidine incorporation ,(cpm -?r SE) into human 
peripheral T- and B-enriched lymphocyte populationsa 
in the presence of PA-II, PHA and Con A 
Mitogen added Cell population 
@g/ml) 
T-enriched B-enriched 
_ 1809 k 749 2168 + 1552 
PA-II (60) 88659 + 14610 8184 + 1239 
PHA (25) 94109 k 18841 10175 k 887 
Con A (12.5) 97475 f 22047 3073 f 242 
a T- and B-enriched cell populations were obtained as 
described in section 2 
15 30 
PA-II CONCENTRATION (+ig+-d’) 
Fig. 1. Dose response of [3H]thymidine incorporation 
into murine splenocytes timulated with PA-II. 
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15 dml), the mitogenicity obtained with 
sialidase-treated cells was stronger than that ob- 
tained with untreated cells (table 2). The PA-II 
mitogenicity for these cells was similar to that ob- 
tained with PHA and Con A (table 1). The sugar 
specificity of the mitogenic effect of PA-II towards 
the human lymphocytes was demonstrated by its 
Fig.2. [3H]Thymidine incorporation into murine 
splenocytes without mitogen (0) or with: PA-II 
(15pg/ml) (a), PA-II (lSpg/ml) together with methyl 
a-D-galactoside (0.02 M) (0) and PA-II (15 pg/ml) 
together with L-fucose (0.05 M) (0). 
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inhibition with L-fucose (table 1). L-Fucose at the 
same concentration did not inhibit lymphocyte 
transformation by Con A or PHA (table 1). The T 
lymphocyte-enriched population was shown to be 
more strongly stimulated by PA-II than the B 
lymphocyte-enriched fraction. These results were 
similar to those obtained with Con A and PHA 
(table 3). 
PA-II was also shown to be mitogenic for 
murine splenocytes (figs 1,2) with maximal effect 
at concentrations of about 15 pg/ml. Higher con- 
centrations were inhibitory, resulting in a bell- 
shaped curve (fig.1). The stimulating effects of 
PA-II on the murine splenocytes was also 
specifically inhibited by L-fucose (fig.2). Methyl a- 
D-galactoside did not inhibit the mitogenic 
stimulation (fig.2). 
4. DISCUSSION 
Mitogenic stimulation is one of the most 
dramatic effects of the interaction of lectins with 
cells [l]. Most of the studies on mitogenic stimula- 
tion were performed with plant and animal lectins 
[l]. We have shown that a bacterial lectin from 
Pseudomonas aeruginosa, which binds D- 
galactose and its derivatives, PA-I, is mitogenic for 
human T lymphocytes 181. In the present com- 
munication we report that the second lectin of the 
same Pseudomonas (which binds L-fucose and D- 
mannose) PA-II, also agglutinates lymphocytes 
and is mitogenic. It agglutinates and stimulates 
both human T lymphocytes and murine 
splenocytes as the classical plant lectins PHA and 
Con A (figs 1,2 and tables l-3). At low lectin con- 
centrations (up to 15 pg/ml) there was a maximal 
stimulation of the murine splenocytes, without any 
enzyme treatment of the cells (fig.1). At the same 
concentration, sialidase-treated human peripheral 
lymphocytes were stimulated better than the un- 
treated cells (table 2). The sialidase pretreatment of 
the cells enhanced their agglutination by the lectin. 
The untreated human lymphocytes were stimulated 
to the same extent as the sialidase-treated ones in 
the presence of higher Iectin concentrations 
(75 pg/ml, table 2). Both the agglutination and the 
mitogenic stimulation of the human peripheral 
lymphocytes and the murine splenocytes were 
shown to be dependent on the sugar specificity of 
the lectin: L-fucose at 0.05 M concentration in- 
hibited them (table 1 and fig.2). The inhibition by 
the L-fucose was specific to the lectin active site 
(not an unspecific toxic effect) since this sugar was 
not inhibitory in the mitogenic system containing 
Con A or PHA instead of PA-II (table 1). 
The inhibition of the mitogenic effect of PA-II 
by L-fucose was important for exclusion of the 
possibility that other components of the bacterium 
were involved in it. Bacterial LPS is known to be 
mitogenic for B lymphocytes. The possibility that 
contamination by PA-I was involved in this 
mitogenic stimulation was also excluded by addi- 
tion of methyl a-D-galactoside which was not in- 
hibitory for the PA-II induced mitogenicity (fig.2). 
Although the inhibition of the PA-II mitogenic 
effect by L-fucose indicates that the effect is 
specifically induced by this lectin, it does not point 
to an L-fucose-bearing molecule as the exclusive 
receptor. PA-II was also shown to react with D- 
mannose in addition to L-fucose. Therefore, it is 
possible that the mitogenic stimulation involves 
mannose-bearing receptors. External L-fucose 
may compete with the interactions of the lectin 
with both sugar types. 
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